This proposed research is aimed to investigate the efficacy and safety of combined cytidine- and creatine-containing drug and dietary supplement in treating bipolar depression and to evaluate changes in relevant brain biochemical metabolism using magnetic resonance spectroscopy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
Valproate: Week0-8: 300mg/day
Ewha Womans University Medical Center
Seoul, South Korea
Change from baseline in depressive symptom scores at 4 weeks
Time frame: Baseline and at 4 weeks
Change from baseline in depressive symptom scores at 8 weeks
Time frame: Baseline and at 8 weeks
Changes in brain Glx (glutamate+glutamine) level assessed using magnetic resonance spectroscopy at baseline and 8 weeks
Time frame: Baseline and at 8 weeks
Number of participants with adverse events
Time frame: 4 weeks
Number of participants with adverse events
Time frame: 8 weeks
Changes in brain phosphocreatine level assessed using magnetic resonance spectroscopy at baseline and 8 weeks
Time frame: Baseline and at 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.